Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
Guang Chen, Li Chen, Yun Zhang, et al.
The International Journal of Neuropsychopharmacology (2022) Vol. 25, Iss. 4, pp. 269-279
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Long-term safety of ketamine and esketamine in treatment of depression
Sina Nikayin, Eva Murphy, John H. Krystal, et al.
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 777-787
Closed Access | Times Cited: 69
Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?
Kenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience (2024)
Open Access | Times Cited: 28
Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial
Shuo Wang, Chun-Mei Deng, Yuan Zeng, et al.
BMJ (2024), pp. e078218-e078218
Open Access | Times Cited: 22
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Konstantinos Ν. Fountoulakis, Athanasios Saitis, Alan F. Schatzberg
American Journal of Psychiatry (2025)
Closed Access | Times Cited: 4
Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research
Roger S. McIntyre, Angela T.H. Kwan, Rodrigo B. Mansur, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 21-32
Closed Access | Times Cited: 2
Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine
David S. Mathai, Sandeep M. Nayak, David B. Yaden, et al.
Psychopharmacology (2023) Vol. 240, Iss. 4, pp. 827-836
Closed Access | Times Cited: 30
Ketamine and its two enantiomers in anesthesiology and psychiatry: A historical review and future directions
Kenji Hashimoto, Mingming Zhao, Tingting Zhu, et al.
Journal of Anesthesia and Translational Medicine (2024) Vol. 3, Iss. 3, pp. 65-75
Open Access | Times Cited: 11
Toward Synergies of Ketamine and Psychotherapy
David S. Mathai, Victoria Mora, Albert Garcia‐Romeu
Frontiers in Psychology (2022) Vol. 13
Open Access | Times Cited: 32
Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study
Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 30
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin, et al.
Psychopharmacology (2023) Vol. 240, Iss. 7, pp. 1547-1560
Open Access | Times Cited: 18
Esketamine and Psilocybin—The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review
Dominika Psiuk, Emilia Nowak, Natalia Dycha, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11450-11450
Open Access | Times Cited: 26
Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review
Matteo Di Vincenzo, Vassilis Martiadis, Bianca Della Rocca, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 5
Effects of repeated intravenous esketamine administration on affective biases
Christine Reif-Leonhard, Shannon N. Millard, Dorsa Ferdowssian, et al.
The World Journal of Biological Psychiatry (2025), pp. 1-14
Open Access
The ketamine chameleon: history, pharmacology, and the contested value of experience
Danny Diep, Sara de la Salle, Julien Thibault Lévesque, et al.
Expert Review of Clinical Pharmacology (2025)
Closed Access
Is there a risk of esketamine misuse in clinical practice?
Carlos Roncero, M. Merizalde Torres, Néstor Szerman, et al.
Therapeutic Advances in Drug Safety (2025) Vol. 16
Open Access
The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
Maria Pepe, Giovanni Bartolucci, Ilaria Marcelli, et al.
Brain Sciences (2023) Vol. 13, Iss. 10, pp. 1494-1494
Open Access | Times Cited: 10
Efficacy of ketamine versus esketamine in the treatment of perioperative depression: A review
Wen Wen, Wenjing Zhao, Xing Xia, et al.
Pharmacology Biochemistry and Behavior (2024) Vol. 242, pp. 173773-173773
Closed Access | Times Cited: 3
Personalized use of ketamine and esketamine for treatment-resistant depression
Gustavo C. Medeiros, Isabella Demo, Fernando S. Goes, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Aistė Lengvenytė, Robertas Strumila, Émilie Olié, et al.
European Neuropsychopharmacology (2022) Vol. 57, pp. 88-104
Open Access | Times Cited: 15
Listening to music during intranasal (es)ketamine therapy in patients with treatment-resistant depression correlates with better tolerability and reduced anxiety
Johannes Hauser, Jan Sarlon, Timur Liwinski, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 2
The Use of Ketamine for the Treatment of Anhedonia in Depression
Liliana Patarroyo-Rodríguez, Stefanie Cavalcanti, Jennifer L. Vande Voort, et al.
CNS Drugs (2024) Vol. 38, Iss. 8, pp. 583-596
Closed Access | Times Cited: 2
Disembodiment and Affective Resonances in Esketamine Treatment of Depersonalized Depression Subtype: Two Case Studies
Pietro Sarasso, Martina Billeci, Irene Ronga, et al.
Psychopathology (2024), pp. 1-12
Closed Access | Times Cited: 2
Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome
Jack D. C. Dahan, David Dadiomov, Tijmen Bostoen, et al.
npj Mental Health Research (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 2
Mapping consent practices for outpatient psychiatric use of ketamine
David S. Mathai, Scott M. Lee, Victoria Mora, et al.
Journal of Affective Disorders (2022) Vol. 312, pp. 113-121
Closed Access | Times Cited: 11
Differential effectiveness between Ketamine and Esketamine: the predictive role of dissociative features. A treatment-resistant depression case
Nicola Ragone, Barbara Barbini, C. Passani, et al.
International Clinical Psychopharmacology (2023) Vol. 39, Iss. 2, pp. 117-119
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top